Asset
BELZUPACAP SAROTALOCAN
Aura Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05483868 | phase1 | active_not_recruiting | 2022-09-26 | 2027-03-01 | Aura Biosciences | A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer |
| NCT04417530 | phase2 | completed | 2020-08-05 | 2024-04-22 | Aura Biosciences | Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma |
| NCT06643884 | phase2 | recruiting | 2024-12-16 | 2026-11-30 | Aura Biosciences | Suprachoroidal Administration in Subjects With Metastases to the Choroid |
FDA applications (0)
This company has no applications containing this asset.